Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00061815 · ClinicalTrials.gov registry record · Phase 3
Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 102
- Enrollment target
NCT00061815 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 102 participants.
The verdict
NCT00061815, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 102 participants
- Enrollment target
Study Summary
The purpose of this study is to compare overall survival in patients with previously-treated metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX4) and cetuximab with FOLFOX4 alone.
Interventions
- DRUG 5-fluorouracil
- DRUG oxaliplatin
- BIOLOGICAL cetuximab
- DRUG leucovorin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2003-03 |
| Est. Completion | 2005-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00061815
The ClinicalTrials.gov registry entry for NCT00061815 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which 5-fluorouracil is the first listed.
NCT00061815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00061815 about?
NCT00061815 is a clinical study titled "Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer". The purpose of this study is to compare overall survival in patients with previously-treated metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX4) and cetuximab with FOLFOX4 alone.
What is the current status of trial NCT00061815?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 102 participants. The study started on 2003-03. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00061815?
The interventions under investigation include: 5-fluorouracil (DRUG), oxaliplatin (DRUG), cetuximab (BIOLOGICAL), leucovorin (DRUG).
Who is sponsoring clinical trial NCT00061815?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.